Td Asset Management Inc Atara Biotherapeutics, Inc. Transaction History

Td Asset Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$0.44 - $1.22 $192,192 - $532,896	436,800 New	436,800 $301,000
Q3 2019 Nov 07, 2019	SELL	$12.03 - $19.94 $162,669 - $269,628	-13,522 Closed	0 $0
Q2 2019 Aug 01, 2019	SELL	$19.05 - $41.04 $704,221 - $1.52 Million	-36,967 Reduced 73.22%	13,522 $272,000
Q1 2019 May 08, 2019	BUY	$28.4 - $41.74 $105,080 - $154,438	3,700 Added 7.91%	50,489 $2.01 Million
Q4 2018 Feb 01, 2019	BUY	$30.9 - $42.97 $40,170 - $55,861	1,300 Added 2.86%	46,789 $1.63 Million
Q3 2018 Nov 01, 2018	BUY	$35.05 - $43.5 $84,120 - $104,400	2,400 Added 5.57%	45,489 $1.88 Million
Q2 2018 Jul 31, 2018	BUY	$35.15 - $51.45 $70,300 - $102,900	2,000 Added 4.87%	43,089 $1.58 Million
Q1 2018 May 11, 2018	BUY	$18.0 - $48.35 $739,602 - $1.99 Million	41,089 New	41,089 $1.6 Million

3.07M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $720M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.